Mesothelioma and Immune Profile of Pleural Effusions
Conclusions: SS1P is well tolerated with pleuritis as the DLT at the highest dose level
. Evidence of clinical activity was noted in a group of heavily pretreated patients. Phase II clinical trials of SS1P are being planned for malignant mesothelioma and other mesothelin-expressing malignancies."
Mesothelioma and Immune Profile of Pleural Effusions